Pharmaceutical manufacturers of Sildenafil citrate

With almost a century of experience behind it, Bioindustria LIM is today a point of reference at a national and international level, both for the specialization of its production and for the modernity of its research laboratories and its industrial plants.

Polpharma Group serves as a top-tier pharmaceutical manufacturer in Europe and a reliable partner for pharmaceutical firms globally. With a wide range of products (Rx, CHC, APIs), expert services, and competencies across the value chain, along with extensive knowledge of local CEE/CIS markets, it provides distinct growth opportunities for B2B partners. Collaborating with Polpharma Group offers access to a supportive environment, guidance from skilled professionals, and cutting-edge resources. The company actively seeks partners across various areas of operation, from product development and production to commercial cooperation. Additionally, Polpharma API, a Poland-based CDMO specializing in active pharmaceutical ingredients (APIs), stands as a significant European API supplier, catering to pharmaceutical companies worldwide. The company is in the process of a $45 million manufacturing expansion, incorporating HPAPI and cryogenic technologies, with investments in a pilot plant and R&D capabilities. Operations are set to expand from mid-2023, with full completion expected by 2026.

Cadila Pharmaceuticals Ltd. is one of the largest privately-held pharmaceutical companies in India. Over the past seven decades, we have been developing and manufacturing affordable medicines for patients around the world. Our innovation-led drug discovery processes ensure the health and well-being of people around the world. Our enhanced investment in innovation and a strong track record in research and development have produced medical miracles that have changed lives and made a profound impact on real life.

MSN Group is the fastest growing research-based pharmaceutical company based out of India. Founded in 2003 with a mission to make health care affordable, this Hyderabad-based venture has Fifteen API and Six finished dosage facilities established across India & USA. The group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals to make them more accessible.

Reyoung Pharmaceutical Co., Ltd., established in 1966, is a modern comprehensive pharmaceutical company. Reyoung is given the title of National Trustworthy Company for Contract and Credit, Grade AAA Credit Company and Credit Company of Shandong Medical Industry. In the past 50 years, Reyoung inherits the mission “Reyoung Pharma., Benefit the public”, insists the business concept “Innovation is the basis, Product quality is first”. Never stop exploration and innovation, forging ahead with determination, and realizing the sustainable healthy development.

Rakshit Corporation, has a long-standing presence in the field of API production, operating for more than 20 years and possessing facilities that are sanctioned by USFDA, Japan-PMDA, Korean FDA, and multiple approved CEPs. Rakshit stands as the primary global producer of Sildenafil Citrate API and its intermediates, specializing in the production of Erectile Dysfunction APIs. The Rakshit conglomerate is equipped with three manufacturing units that comply with cGMP standards.

Amoli has been working collaboratively with some of the leading global healthcare players since 3 decades. Our strength comes from our expertise in process chemistry further bolstered by our EDQM and USFDA approved facilities allowing us to cater to the needs of the pharmaceutical industry globally. We offer APIs from a wide range of therapeutic classes like NSAIDS, Antifungals, Antidepressants, Hypolipidemics etc. With the support our state-of-the-art R&D centre, we are constantly expanding our product range and foraying into newer therapeutic categories.

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (Abbreviated Name: Jiuzhou Pharma, Stock Code: 603456.SH), founded in 1998 and headquartered in Taizhou, Zhejiang, is a leading contract development and manufacturing organization (CDMO) that successfully evolved from a generic API manufacturer. We provide pharmaceutical companies worldwide with one-stop innovative drug development and manufacturing solutions and services throughout the development lifecycle of an innovative drug—from preclinical chemical manufacturing and control (CMC) through phase I/II/III clinical trials and new drug applications (NDA) to commercialization. As a leader in green pharmaceutical manufacturing, we have developed frontier environmentally-friendly pharmaceutical technologies with independent intellectual property rights. We are committed to providing our customers with industry-leading technical solutions that enhance R&D efficiency and success while reducing costs. Serve life, guard health. We are committed to becoming a distinguished global life science company that provides innovative drug solutions to help our partners accelerate the time to market of innovative drugs and benefit patients worldwide.

VIATRIS™ represents a fresh approach to healthcare, dedicated to ensuring medicine accessibility, promoting sustainable practices, pioneering creative remedies, and enhancing patient results. Founded in 2020 through the merger of Mylan and Upjohn, Viatris unites top-notch scientific, production and distribution skills with established regulatory, medical and commercial proficiencies.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Polepharma has been organizing and advancing the pharmaceutical industry in France, specializing in the biopharmaceutical sector for two decades. It has developed into the leading European hub for drug production, facilitating collaboration between excellence centers and industry stakeholders. Polepharma is committed to three collective principles, including the bold ambition to position France as the global leader in pharmaceutical development. On the other hand, Polpharma is a prominent CDMO and API producer based in Poland. With over 70 years of expertise, it stands as the largest API manufacturer in Poland, offering a comprehensive range of materials from clinical quantities to market supply. The company has fully integrated its operations, covering R&D to manufacturing, to provide cost-effective and timely solutions to its clients. Furthermore, Polpharma has made significant investments to enhance its API plant in Starogard Gdanski, incorporating HPAPI and cryogenic technologies, along with a pilot plant and R&D capabilities.

We at Raks are dedicated to develop and manufacture active pharmaceutical ingredients and intermediates. We are committed to create value through intellectual property, quality systems and customer relation across the globe. We are research driven company providing cost effective and environmental friendly technologies with safety and quality as primary focus.

Azico Biophore India Pvt. Ltd. operates a facility for manufacturing active pharmaceutical ingredients (APIs) which has undergone successful inspections by the US FDA on three occasions, with the most recent audit conducted in February 2019. The company holds 22 active Drug Master Files (DMFs). They offer a Customized Business Model, providing supplies from conceptualization to commercialization, as well as contract manufacturing of APIs, Key Starting Materials (KSMs), and Intermediates.

Smilax Laboratories Limited is a leading vertically integrated pharmaceutical organization, manufacturing Active Pharmaceutical Ingredients, API Intermediates and NDDS/Pellets for the generics market across the world. The position today built by Smilax is due to its cutting edge research , world class manufacturing and a truly global supply chain management.

Shree Venkatesh International Limited has established itself as a rapidly growing and distinguished Indian company dedicated to the production, promotion, and export of Hormonal products. Our state-of-the-art facility is equipped with advanced technologies specifically designed for a wide range of Gynecological, IVFs, and Contraceptives Hormonal products. At Shree Venkatesh International Limited, we tirelessly strive to develop highly efficient and safe hormonal products and make them accessible at the most competitive prices globally. Our portfolio includes Injectables, lyophilized powder, and hormonal Oral tablets, contributing to the enhancement of reproductive health on a global scale. Our WHO-GMP (India) plant has been inspected and approved by regulatory bodies in Yemen (SBDMA), Kenya (PPB), Nigeria (NAFDAC), Cambodia, and the Philippines. We have plans to extend our product reach to countries in the CIS, African, Southern Asian, Southern American, PIC/s, and MENA regions. For further information, please visit www.shreevenkatesh.com. Shree Venkatesh International Limited is an ISO9001:2008 Certified company registered under the Registrar of Companies Act, specializing in the export of Generic Medicines, Pharmaceutical formulations, and Bulk drugs from India. The company is based in Gujarat, which is renowned as the Manufacturing Hub for Pharmaceutical formulations in India.

Established as Toho Bussan Koeki, LTD. through investment from Nikko Shoji, Ltd. Engaged in a partnership with Permachem Corporation based in Florida, USA, to manufacture and distribute Permachem products in Japan and Southeast Asia. The location of PERMACHEM ASIA LTD. is in Kikugawa, Shizuoka, Japan, and is affiliated with the Other Chemical Product and Preparation Manufacturing Industry, along with 6 other companies within the PERMACHEM ASIA LTD. corporate network.

Established in the year 2000 as Dongwoo Shintech Co., Ltd., INIST ST has emerged as a pioneer in the advancement of pharmaceutical raw materials and the technology for synthesizing raw materials. Guided by the principles of transformation, innovation, and a passion for life, INIST ST has been engaged in the exploration and production of high-caliber generic raw materials and enhanced drugs through salt modification, commencing with the development of treatments for cerebrovascular diseases and distributing them both nationally and globally. Backed by unwavering trust and expertise, it is utilized as a contrast agent for heart disease and serves as the basis for numerous original active ingredients.